Cell-based therapy enabling safe haploidentical haematopoietic stem cell transplantation (HSCT) for the treatment of haematological malignancies. Phase III ongoing in Europe for high-risk leukaemia.
A novel VTA for the treatment of solid tumours. Phase III trial in mesothelioma ongoing in Europe and US. Randomised Phase II trials ongoing in non-small-cell lung cancer, ovarian cancer, soft tissue sarcomas and mesothelioma as maintenance treatment. Completed Phase II trials in colorectal cancer, liver cancer and small-cell lung cancer.
MolMed S.p.A. - via Olgettina, 58 – 20132 Milan (Italy) – Tax identification number: 11887610159 – Share capital at 30/05/2011: € 43,609,036.42 fully paid - Milan Company Registry nr. 11887610159
